Drugs / MHB036C for Injection
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07229599 | May 2025 → May 2029 expected | lung cancer | Minghui Pharmaceutical (Hangzhou) Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MHB036C for Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07229599 ↗ |
| Route | Intravenous | “IV administration” NCT07229599 ↗ |